TORONTO, Sept. 19, 2012 /CNW/ - BIOSENTA INC. (CNSX: ZRO) (the "Company"). The Company is pleased to announce that it has
obtained a Drug Identification Number from Health Canada, Therapeutic
Products Directorate, for "Zeromold", the Company's retail
anti-microbial product. The Company has commenced manufacturing
Zeromold and expects to fill and ship its first order, for
approximately $600,000, to its exclusive Canadian distributor, F.T.R.
Products Group Inc. in the coming weeks. F.T.R. Products Group is one
of Canada's leading importer, manufacturer and distributor of home
improvement products, including plumbing, bath, electrical, hardware,
cleaning solutions and seasonal merchandise.
"This is an exciting time for the Company", said Bruce Lewis, the
President & Chief Executive Officer of Biosenta. "The Company has
successfully developed a new and unique line of business in a little
over a period of one year with the help and support of its many
investors, its directors and employees and its suppliers and
distributor. We look forward to developing and expanding the product
"We are looking forward to fulfilling our pre-orders for Zeromold and
successfully launching the product right across Canada", said Frank
Curcio, President, F.T.R. Products Group Inc.
About BIOSENTA Inc.
BIOSENTA Inc.'s line of retail anti-microbial products will effectively
kill mould, bacteria and fungi on contact and prevent re-growth. These
products address the demand created by the mounting health and
environmental concerns. Mould can affect the immune system, nervous
system, liver, kidneys, blood and cause brain damage.
BIOSENTA will also manufacture and distribute an anti-microbial filler.
Calcium Carbonate is one of the most common fillers used industrially.
It is susceptible like other fillers that hold moisture to attracting
mould. Annual global revenue in the calcium carbonate filler industry
approximates 140 billion dollars. BIOSENTA will produce anti-microbial
filler that performs 'filling' and 'bulking' functions like calcium
carbonate. BIOSENTA's filler product will not attract moisture and
consequently mould infestation. BIOSENTA's filler with its
anti-microbial high ph core in individual particles will enhance
commercial product life and eradicate a broad spectrum of known
bacteria, fungi, algae and other micro-organisms by suppression of
This release may contain forward-looking statements information and
statements which constitute "forward-looking information" under
Canadian securities law and which may be material regarding, among
other things, the Company's beliefs, plans, objectives, estimates,
intentions and expectations with respect to its capital and funding
plans. Inherent in the forward-looking information and statements are
known and unknown risks, uncertainties and other factors beyond the
Company's ability to control or predict, which give rise to the
possibility that the Company's predictions, forecasts, expectations or
conclusions will not prove to be accurate, that its assumptions may not
be correct and that the Company's plans, objectives and statements will
not be achieved. Actual results or developments may differ materially
from those contemplated by the forward-looking information and
statements. Consequently, undue reliance should not placed on such
On behalf of the Board of Directors of BIOSENTA Inc.
The CNSX has in no way passed upon the merits of the proposed
transaction and has neither approved nor disapproved of the contents of
this press release. Neither the CNSX nor its Regulation Services
Provider (as such term is defined in the policies of the CNSX) accepts
responsibility for the adequacy or accuracy of this release.
SOURCE: BIOSENTA Inc.
For further information:
Bruce Lewis, President & Chief Executive Officer
1120 Finch Avenue West, Suite 503
Toronto, Ontario M3J 3H7
(416) 410 2019